文献速递头颈外科咽喉与嗓音

治疗前CT肿瘤体积定量与T4a期喉鳞癌肿瘤学结局的相关性

Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx.
PubMed 文献 · Head Neck · 2017-05-02

本研究回顾性分析2000-2011年124例T4a期喉鳞癌患者,评估治疗前CT测定的原发肿瘤体积对生存和疾病控制的影响。肿瘤体积≥21 cm³是更差疾病特异性生存、无事件生存、无复发生存、非肿瘤原因特异性生存和总生存的独立相关因素。

要点

  • 肿瘤体积≥21 cm³与T4a期喉鳞癌更差的总生存独立相关。
  • 保喉治疗组中体积≥21 cm³者5年OS显著低于<21 cm³者(42% vs 64%,P=.003)。
  • 全喉切除+放疗组中体积≥21 cm³者5年OS与<21 cm³者无统计学显著差异(50% vs 63%,P=.058)。

核心结论

  • 治疗前基于CT的肿瘤体积是T4a期喉鳞癌结局的独立预后因素。

研究设计与样本

  • 回顾性研究,纳入2000-2011年124例T4a期喉鳞癌患者,收集肿瘤体积测量值并与结局进行相关性分析。

主要发现

  • 保喉治疗患者中,肿瘤体积≥21 cm³者(41例中26例)5年OS显著低于<21 cm³者(42% vs 64%,P=.003)。
  • 全喉切除+放疗患者中,肿瘤体积≥21 cm³者(83例中42例)5年OS与<21 cm³者无统计学显著差异(50% vs 63%,P=.058)。
  • 多因素分析中,肿瘤体积≥21 cm³是更差DSS(P=.004)、无事件生存(P=.005)、RFS(P=.04)、非肿瘤原因特异性生存(P=.02)和OS(P=.0002)的显著独立相关因素。

关键数值与推荐

  • 保喉治疗组:肿瘤体积≥21 cm³者5年OS 42% vs <21 cm³者64%(P=.003)。
  • 全喉切除+放疗组:肿瘤体积≥21 cm³者5年OS 50% vs <21 cm³者63%(P=.058)。

临床怎么用

  • 治疗前CT测定的原发肿瘤体积可作为T4a期喉鳞癌的预后评估指标。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The purpose of this study was to determine the impact of CT-determined pretreatment primary tumor volume on survival and disease control in T4a laryngeal squamous cell carcinoma (SCC). METHODS: We retrospectively reviewed 124 patients with T4a laryngeal cancer from 2000-2011. Tumor volume measurements were collected and correlated with outcomes. RESULTS: Five-year overall survival (OS) for patients with tumor volume ≥21 cm3 treated with larynx preservation (n = 26 of 41) was significantly inferior compared to <21 cm3 (42% vs 64%, respectively; P = .003). Five-year OS for patients with tumor volumes ≥21 cm3 in the cohort treated with total laryngectomy followed by radiotherapy (RT; n = 42 of 83) was not statistically significant when compared to <21 cm3 (50% vs 63%, respectively; P = .058). On multivariate analysis, tumor volume ≥21 cm3 was a significant independent correlate of worse disease-specific survival (DSS; P = .004), event-free survival (P = .005), recurrence-free survival (RFS; P = .04), noncancer cause-specific survival (P = .02), and OS (P = .0002). CONCLUSION: Pretreatment CT-based tumor volume is an independent prognostic factor of outcomes in T4a laryngeal cancer.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Shiao JC, Mohamed ASR, Messer JA, et al. Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx. Head Neck. 2017. PMID: 28464542. doi:10.1002/hed.24804

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。